文献分析结果 http://www.gopubmed.org/web/gopubmed/1?WEB01tmtthi6ec8sxI7IbI0 Mesenchymal cells and leukaemia 381 documents semantically analyzed top author statistics 1 2 Top Years Publications 2009 53 2008 49 2007 44 2006 31 2005 22 2003 18 2004 17 2010 12 1999 12 1993 12 1994 11 2002 10 2000 9 2001 8 1998 8 1996 8 1988 7 1995 6 1992 5 1991 5 1 2 1 2 Top Countries Publications USA 101 China 38 Japan 32 Germany 24 Italy 22 United Kingdom 19 France 13 Sweden 11 Australia 8 Taiwan 8 Canada 8 Israel 7 Spain 6 Netherlands 6 Belgium 5 Switzerland 5 South Korea 4 Austria 4 Norway 3 Finland 3 1 2 1 2 3 ... 9 Top Cities Publications Houston 15 Tokyo 11 Boston 11 London 8 Beijing 6 Huddinge 6 Baltimore 6 Paris 5 Tianjin 5 New Orleans 5 Taipei 4 Tbingen 4 Salamanca 4 Naples 4 Basel 4 Memphis 4 New York 4 Freiburg 4 Vancouver 4 Adelaide 3 1 2 3 ... 9 1 2 3 ... 11 Top Journals Publications Leukemia 44 Exp Hematol 12 Blood 11 Cancer Res 10 J Cell Physiol 8 Zhongguo Shi Yan Xue Ye Xue Za Zhi 8 Haematologica 6 Stem Cells 6 Leukemia Res 6 Int J Oncol 5 Biol Blood Marrow Transplant 4 Stem Cells Dev 4 J Biol Chem 4 Oncogene 4 P Natl Acad Sci Usa 4 J Hematoth Stem Cell 4 Leukemia Lymphoma 4 Br J Haematol 3 Brit J Haematol 3 Ann Hematol 3 1 2 3 ... 11 1 2 3 ... 170 Top Terms Publications Mesoderm 357 Humans 312 mesenchymal cell proliferation 264 mesenchymal cell differentiation 263 mesenchymal cell development 262 Leukemia 262 stem cell development 187 stem cell differentiation 187 Animals 140 Bone Marrow 136 Neoplasms 129 Patients 126 Genes 122 Proteins 120 Cells, Cultured 116 Mesenchymal Stem Cells 111 Tissues 95 Mice 95 Adult 92 Bone Marrow Cells 89 1 2 3 ... 170 1 2 3 ... 107 Top Authors Publications Ringdn O 5 Zhao R 5 Fang B 5 Eaves C 5 Andreeff M 4 Song Y 4 Katoh M 3 Gorin N 3 Dazzi F 3 Zou P 3 Zhao Z 3 LeBlanc K 3 Sundberg B 3 Han Q 3 Konopleva M 3 Tabe Y 3 Inoue I 3 Ikeda R 3 Gao S 3 Zhang G 3 1 2 3 ... 107 最新研究进展 Nature. 2010 Apr 8;464(7290):852-7. Epub 2010 Mar 21. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Raaijmakers MH , Mukherjee S , Guo S , Zhang S , Kobayashi T , Schoonmaker JA , Ebert BL , Al-Shahrour F , Hasserjian RP , Scadden EO , Aung Z , Matza M , Merkenschlager M , Lin C , Rommens JM , Scadden DT . Center for Regenerative Medicine, Massachusetts General Hospital and Harvard Medical School CPZN, USA. hraaijmakers@partners.org Comment in: Cell Stem Cell. 2010 May 7;6(5):399-400. Abstract Mesenchymal cells contribute to the 'stroma' of most normal and malignant tissues, with specific mesenchymal cells participating in the regulatory niches of stem cells. By examining how mesenchymal osteolineage cells modulate haematopoiesis, here we show that deletion of Dicer1 specifically in mouse osteoprogenitors, but not in mature osteoblasts, disrupts the integrity of haematopoiesis. Myelodysplasia resulted and acute myelogenous leukaemia emerged that had acquired several genetic abnormalities while having intact Dicer1. Examining gene expression altered in osteoprogenitors as a result of Dicer1 deletion showed reduced expression of Sbds, the gene mutated in Schwachman-Bodian-Diamond syndrome-a human bone marrow failure and leukaemia pre-disposition condition. Deletion of Sbds in mouse osteoprogenitors induced bone marrow dysfunction with myelodysplasia. Therefore, perturbation of specific mesenchymal subsets of stromal cells can disorder differentiation, proliferation and apoptosis of heterologous cells, and disrupt tissue homeostasis. Furthermore, primary stromal dysfunction can result in secondary neoplastic disease, supporting the concept of niche-induced oncogenesis. PMID: 20305640 Publication Types, MeSH Terms, Substances Publication Types: Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't MeSH Terms: Animals Bone Marrow/metabolism Bone Marrow/pathology Bone and Bones/metabolism Bone and Bones/pathology* Cell Differentiation Cell Lineage Female Gene Deletion Hematopoiesis/genetics Leukemia, Myeloid, Acute/genetics Leukemia, Myeloid, Acute/metabolism Leukemia, Myeloid, Acute/pathology* Male Mesoderm/cytology Mice Myelodysplastic Syndromes/genetics Myelodysplastic Syndromes/metabolism Myelodysplastic Syndromes/pathology* Osteoblasts/metabolism Osteoblasts/pathology Phenotype Proteins/genetics Proteins/metabolism Ribonuclease III/deficiency Ribonuclease III/genetics Ribonuclease III/metabolism Sarcoma, Myeloid/genetics Sarcoma, Myeloid/metabolism Sarcoma, Myeloid/pathology Stem Cell Niche/metabolism Stem Cell Niche/pathology Stem Cells/metabolism Stem Cells/pathology* Stromal Cells/metabolism Stromal Cells/pathology Substances: Proteins Sbds protein, mouse Ribonuclease III LinkOut - more resources Full Text Sources: Nature Publishing Group EBSCO Ovid Technologies, Inc. Swets Information Services Other Literature Sources: COS Scholar Universe Evaluations and comments from leading researchers and clinicians - Faculty of 1000 Medicine Medical: Stem Cells - MedlinePlus Health Information Miscellaneous: Mouse Genome Informatics (MGI) Libraries: LinkOut Holdings PUBMED数据库中的相关文献 Filter your results: All (100) 共100篇 Review (16) 综述16篇 Free Full Text (33) 免费全文33篇 Related citations Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes. Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes. Varga G, Kiss J, Vrkonyi J, Vas V, Farkas P, Plczi K, Uher F. Pathol Oncol Res. 2007; 13(4):311-9. Epub 2007 Dec 25. Bone marrow stroma in childhood myelodysplastic syndrome: composition, ability to sustain hematopoiesis in vitro, and altered gene expression. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Colmone A, Amorim M, Pontier AL, Wang S, Jablonski E, Sipkins DA. Science. 2008 Dec 19; 322(5909):1861-5. Review Stromal abnormalities in neoplastic bone marrow diseases. Review Stromal abnormalities in neoplastic bone marrow diseases. Dhrsen U, Hossfeld DK. Ann Hematol. 1996 Aug; 73(2):53-70. Review Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review.
http://news.sciencenet.cn//htmlnews/2010/4/230670.shtm 《科学》:我国白血病研究又获重大突破 发现抗急性早幼粒细胞白血病药物三氧化二砷的作用靶点 上海交通大学医学院附属瑞金医院上海血液学研究所/医学基因组学国家重点实验室4月9日在国际权威杂志《科学》( Science )上发表了三氧化二砷治疗急性早幼粒细胞性白血病(APL)分子机制的最新研究成果,该研究揭示了癌蛋白PML-RAR 是砷剂治疗APL的直接药物靶点。他们发现三氧化二砷直接与癌蛋白PML端的锌指结构中的半胱氨酸结合,诱导蛋白质发生构象变化和多聚化,继而发生SUMO化、泛素化修饰而被蛋白酶体降解。癌蛋白的降解最终导致白血病细胞走向分化和凋亡。使APL成为人类急性白血病分子靶向治疗取得临床治愈的成功范例。这一成果丰富了APL靶向治疗的理论,对于推动其它类型白血病和实体瘤的分子靶向治疗研究也具有十分重要的指导意义。 http://www.sciencemag.org/cgi/content/abstract/328/5975/240 Science 9 April 2010: Vol. 328. no. 5975, pp. 240 - 243 DOI: 10.1126/science.1183424 Prev | Table of Contents | Next Reports Arsenic Trioxide Controls the Fate of the PML-RAR Oncoprotein by Directly Binding PML Xiao-Wei Zhang, 1 ,* Xiao-Jing Yan, 1 ,* Zi-Ren Zhou, 2 Fei-Fei Yang, 3 Zi-Yu Wu, 3 Hong-Bin Sun, 4 Wen-Xue Liang, 1 Ai-Xin Song, 2 Valrie Lallemand-Breitenbach, 5 Marion Jeanne, 5 Qun-Ye Zhang, 1 Huai-Yu Yang, 6 Qiu-Hua Huang, 1 Guang-Biao Zhou, 7 Jian-Hua Tong, 1 Yan Zhang, 1 Ji-Hui Wu, 4 Hong-Yu Hu, 2 Hugues de Th, 5 ,8 Sai-Juan Chen, 1 ,8 , Zhu Chen 1 ,8 , Arsenic, an ancient drug used in traditional Chinese medicine, has attracted worldwide interest because it shows substantial anticancer activity in patients with acute promyelocytic leukemia (APL). Arsenic trioxide (As 2 O 3 ) exerts its therapeutic effect by promoting degradation of an oncogenic protein that drives the growth of APL cells, PML-RAR (a fusion protein containing sequences from the PML zinc finger protein and retinoic acid receptor alpha). PML and PML-RAR degradation is triggered by their SUMOylation, but the mechanism by which As 2 O 3 induces this posttranslational modification is unclear. Here we show that arsenic binds directly to cysteine residues in zinc fingers located within the RBCC domain of PML-RAR and PML. Arsenic binding induces PML oligomerization, which increases its interaction with the small ubiquitin-like protein modifier (SUMO)conjugating enzyme UBC9, resulting in enhanced SUMOylation and degradation. The identification of PML as a direct target of As 2 O 3 provides new insights into the drugs mechanism of action and its specificity for APL. 1 State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, Rui Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, 197 Rui Jin Road II, Shanghai 200025, China. 2 State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (CAS), Shanghai 200031, China. 3 National Synchrotron Radiation Laboratory, University of Science and Technology of China and Beijing Synchrotron Radiation Facility, Institute of High Energy Physics, CAS, Beijing 10004, China. 4 Hefei National Laboratory for Physical Sciences at Microscale and School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230026, China. 5 Universit de Paris 7/INSERM/CNRS UMR 944/7151, Equipe Labellise No. 11 Ligue Nationale Contre le Cancer, Hpital St. Louis, Avenue C. Vellefaux, 75475 Paris CEDEX 10, France. 6 Shanghai Institute of Materia Medica, Shanghai Institutes for Biological Sciences, CAS, Shanghai 201203, China. 7 Laboratory of Molecular Carcinogenesis and Targeted Therapy for Cancer, State Key Laboratory of Biomembrane and Membrane Biotechnology, and Key Laboratory of Stem Cell Development, Institute of Zoology, CAS, Beijing, China. 8 The Ple Sino-Franais de gnomique et de Sciences du vivant de lHpital Rui-Jin, 197 Rui-Jin Road II, Shanghai, China. * These authors contributed equally to this work. To whom correspondence should be addressed. E-mail: zchen@stn.sh.cn